Table 1. Demographic and clinical data of the individuals of this study.
| TT/BT >60 ys (E T-Lep) | TT/BT 20–40 ys (Y T-Lep) | BL/LL >60 ys (E L-Lep) | BL/LL 20–40 ys (Y L-Lep) | Healthy volunteers >60 ys (E HV) | Healthy volunteers 20–40 ys (Y HV) | |
|---|---|---|---|---|---|---|
| N | 25 | 20 | 20 | 22 | 15 | 10 |
| Age (Mean ± SD) | 69.2 ± 7.2 | 31.8 ± 5.4 | 68.1 ± 6.4 | 31.3 ± 5.9 | 77 ± 6.6 | 29.6 ± 6.2 |
| Gender | ||||||
| Male N (%) | 6 (24%) | 12 (60%) | 13 (65%) | 15 (68%) | 7 (47%) | 4 (40%) |
| Female N (%) | 19 (76%) | 8 (40%) | 7 (35%) | 7 (32%) | 8 (53%) | 6 (60%) |
| BI (Mean ± SD) | _ | _ | 3.8 ± 1.3 | 4.3 ± 1.2 | - | - |
| WHO disability grade I or II (%) | 17.40% | 6.20% | 60% | 42.10% | - | - |
| Lepromin Test (Mitsuda mm ± SD) | 6.88 ± 3.99 | 10.07 ± 2.84 | 0 | 0 | - | - |
| History of Reaction (%)* | ||||||
| Type 1 N (%) | 4 (18.2%) | 3 (21.4%) | 4 (22%) | 4 (19%) | - | - |
| Type 2 N (%) | 0 | 0 | 5 (27,8%) | 6 (28,5%) | - | - |
| Time to diagnosis** (Mean±SD) | 12.3 ± 9.4 | 11.3 ± 6.5 | 10.7 ± 11.5 | 12.1 ± 7.5 | - | - |
| Presence of BCG vaccine scar N (%) | 7 (28%) | 17 (85%) | 1 (5%) | 11 (55%) | - | - |
| Scholling degree (years) | ||||||
| 0–5 | 17 (81%) | 3 (20%) | 13 (86.7%) | 9 (42.8%) | - | - |
| > 5 | 4 (19%) | 12 (80%) | 2 (13.3%) | 12 (57.2%) | - | - |
* Up to two years after diagnosis. SD: standard deviation.
** Time in months between onset of symptoms and clinical diagnosis.